Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON: Atezolizumab, Bevacizumab and Cobimetinib in Recurrent Ovarian Cancer
NCT03363867Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2018
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab, cobimetinib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Peter MacCallum Cancer Centre. Started Jul 2018; status: completed.
02
Drugs
atezolizumabbevacizumabcobimetinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03363867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363867.